

## Special Issue

# Targeted Treatment of Lymphoma, Leukaemia and Myeloma

### Message from the Guest Editor

Our understanding of tumor biology has led to the development of several therapies targeting specific genes and proteins involved in the growth and survival of cancer cells. This transformation is most apparent in lymphoma and leukaemia, where therapies targeting Bruton tyrosine kinase, phosphatidylinositol 3-kinase inhibitors, and B-cell lymphoma 2 are already in clinics. The role of the immune system in tumor eradication has led to the development of second-generation CD20 antibodies, chimeric antigen receptor T-cells, and agents acting on key immune checkpoints. Agents acting on DNA methylation or histone protein modification are also active in certain lymphoid malignancies. Several of these agents are superior to conventional chemoimmunotherapy although they are not without risks. This Special Issue will provide a comprehensive overview of current clinical research in lymphoma and leukaemia with special reference to targeted therapies, including the utility of specific drugs/combinations and strategies in various clinical and biological subgroups.

---

### Guest Editor

Prof. Stephen Opat

Department of Haematology, School of Clinical Sciences at Monash Health, Monash University, Wellington Rd, Clayton, VIC 3800, Australia

---

### Deadline for manuscript submissions

closed (20 July 2021)



## Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 4.1  
Indexed in PubMed



[mdpi.com/si/55101](https://mdpi.com/si/55101)

*Journal of Personalized  
Medicine*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://mdpi.com/journal/)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 4.1  
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm.mdpi.com)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM)*, ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

---

### Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

#### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).